APR-246 in Combination With Venetoclax and Azacitidine in TP53-Mutant Myeloid Malignancies
Clinical trial NCT04214860 · COMPLETED
Trial details
- NCT number
- NCT04214860
- Sponsor
- Aprea Therapeutics
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2019-12-13
- Primary completion
- 2022-01-14
- Enrollment
- 51
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.